August 29, 2016 03:13 AM Eastern Daylight Time SAINT PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals announced today that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights (excluding Japan) to SI-6603 (condoliase), a chemonucleolytic product in Phase III development for the treatment of radicular leg pain (e.g. sciatica) due to lumbar disc […]